{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:56:31Z","timestamp":1778864191872,"version":"3.51.4"},"reference-count":43,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["RC-2021-n. 983"],"award-info":[{"award-number":["RC-2021-n. 983"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["22796"],"award-info":[{"award-number":["22796"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["RC-2021-n. 983"],"award-info":[{"award-number":["RC-2021-n. 983"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["22796"],"award-info":[{"award-number":["22796"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007076","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"5 \u00d7 1000 project \u201cActionable targets in clonal progression and systemic spreading of myeloid neoplasms,\u201d","award":["RC-2021-n. 983"],"award-info":[{"award-number":["RC-2021-n. 983"]}]},{"name":"5 \u00d7 1000 project \u201cActionable targets in clonal progression and systemic spreading of myeloid neoplasms,\u201d","award":["22796"],"award-info":[{"award-number":["22796"]}]},{"name":"5 \u00d7 1000 project \u201cActionable targets in clonal progression and systemic spreading of myeloid neoplasms,\u201d","award":["21267"],"award-info":[{"award-number":["21267"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by a chronic inflammatory state that plays a relevant role in the disease pathogenesis (as proven by high levels of inflammatory cytokines with prognostic significance and by a persistent oxidative stress) and by extensive neoangiogenesis in bone marrow (BM) and spleen. Myeloid-derived suppressor cells (MDSCs) are immature cells that expand in patients with cancer, sepsis or chronic inflammation, favoring tumor onset and progression mainly through the decrease in immune surveillance and the promotion of neoangiogenesis. In this paper, we evaluated the presence of circulating MDSCs in PMF patients, the plasmatic factors involved in their mobilization\/expansion and the correlations with laboratory, genetic and clinical parameters. The data indicated that MDSCs could have a relevant role in PMF as a new pathogenic mechanism contributing to explaining the phenotypic diversity observed during the clinical course of the disease, or a potential new target for personalized treatment.<\/jats:p>","DOI":"10.3390\/cancers16142556","type":"journal-article","created":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T08:48:29Z","timestamp":1721206109000},"page":"2556","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Circulating Polymorphonuclear Myeloid-Derived Suppressor Cells (PMN-MDSCs) Have a Biological Role in Patients with Primary Myelofibrosis"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-2761","authenticated-orcid":false,"given":"Rita","family":"Campanelli","sequence":"first","affiliation":[{"name":"Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5254-8532","authenticated-orcid":false,"given":"Adriana","family":"Carolei","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1862-8168","authenticated-orcid":false,"given":"Paolo","family":"Catarsi","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4173-7055","authenticated-orcid":false,"given":"Carlotta","family":"Abb\u00e0","sequence":"additional","affiliation":[{"name":"General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuela","family":"Boveri","sequence":"additional","affiliation":[{"name":"Unit of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Paulli","sequence":"additional","affiliation":[{"name":"Unit of Anatomic Pathology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"},{"name":"Department of Molecular Medicine, Unit of Anatomic Pathology, University of Pavia, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaele","family":"Gentile","sequence":"additional","affiliation":[{"name":"Chemical and Clinics Laboratory, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6516-1751","authenticated-orcid":false,"given":"Monica","family":"Morosini","sequence":"additional","affiliation":[{"name":"Chemical and Clinics Laboratory, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Albertini","sequence":"additional","affiliation":[{"name":"Chemical and Clinics Laboratory, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5885-2842","authenticated-orcid":false,"given":"Stefania","family":"Mantovani","sequence":"additional","affiliation":[{"name":"Research Department, Division of Clinical Immunology\u2014Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8037-0439","authenticated-orcid":false,"given":"Margherita","family":"Massa","sequence":"additional","affiliation":[{"name":"General Medicine 2-Center for Systemic Amyloidosis and High-Complexity Diseases, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8357-7192","authenticated-orcid":false,"given":"Giovanni","family":"Barosi","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-2289","authenticated-orcid":false,"given":"Vittorio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Center for the Study of Myelofibrosis, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/bjh.16576","article-title":"Myelofibrosis biology and contemporary management","volume":"191","author":"Gangat","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/ajh.26857","article-title":"Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Tefferi","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"100711","DOI":"10.1016\/j.blre.2020.100711","article-title":"Role of inflammation in the biology of myeloproliferative neoplasms","volume":"42","author":"Koschmieder","year":"2020","journal-title":"Blood Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/leu.2013.207","article-title":"Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis","volume":"27","author":"Barbui","year":"2013","journal-title":"Leukemia"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/nri2506","article-title":"Myeloid-derived suppressor cells as regulators of the immune system","volume":"9","author":"Gabrilovich","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Consonni, F.M., Porta, C., Marino, A., Pandolfo, C., Mola, S., Bleve, A., and Sica, A. (2019). Myeloid-Derived Suppressor Cells: Ductile Targets in Disease. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00949"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Wang, S., Zhao, X., Wu, S., Cui, D., and Xu, Z. (2023). Myeloid-derived suppressor cells: Key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark. Res., 11.","DOI":"10.1186\/s40364-023-00475-8"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e1494113","DOI":"10.1080\/2162402X.2018.1494113","article-title":"Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: A meta-analysis of 40 studies","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1002\/ijc.33731","article-title":"Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization","volume":"149","author":"Groth","year":"2021","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/978-3-031-26163-3_15","article-title":"Increase in Frequency of Myeloid-Derived Suppressor Cells in the Bone Marrow of Myeloproliferative Neoplasm: Potential Implications in Myelofibrosis","volume":"1408","author":"Kapor","year":"2023","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1002\/cam4.5542","article-title":"Arginase-1+ bone marrow myeloid cells are reduced in myeloproliferative neoplasms and correlate with clinical phenotype, fibrosis, and molecular driver","volume":"12","author":"Bonometti","year":"2023","journal-title":"Cancer Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1189\/jlb.0912461","article-title":"Blood CD33(+)HLA-DR(-) myeloid-derived suppressor cells are increased with age and a history of cancer","volume":"93","author":"Verschoor","year":"2013","journal-title":"J. Leukoc. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"aaf8943","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1365-2141.2009.07726.x","article-title":"Angiogenesis and vascular endothelial growth factor-\/receptor expression in myeloproliferative neoplasms: Correlation with clinical parameters and JAK2-V617F mutational status","volume":"146","author":"Medinger","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1093\/aje\/kwj063","article-title":"The inconsistency of \u201coptimal\u201d cutpoints obtained using two criteria based on the receiver operating characteristic curve","volume":"163","author":"Perkins","year":"2006","journal-title":"Am. J. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41375-020-0926-6","article-title":"Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis","volume":"35","author":"Barosi","year":"2021","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Rasmussen, L.J.H., Petersen, J.E.V., and Eugen-Olsen, J. (2021). Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.780641"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ccr.2004.08.031","article-title":"Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis","volume":"6","author":"Yang","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumour angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1158\/0008-5472.CAN-21-1237","article-title":"The Dawn of Myeloid-Derived Suppressor Cells: Identification of Arginase I as the Mechanism of Immune Suppression","volume":"81","author":"Gabrilovich","year":"2021","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Bergenfelz, C., and Leandersson, K. (2020). The Generation and Identity of Human Myeloid-Derived Suppressor Cells. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00109"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1189\/jlb.0311177","article-title":"Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice","volume":"91","author":"Youn","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1200\/JCO.2008.18.9498","article-title":"Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma","volume":"27","author":"Jensen","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/cncr.26511","article-title":"Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I\/II melanoma","volume":"118","author":"Jensen","year":"2012","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Rao, H.L., Chen, J.W., Li, M., Xiao, Y.B., Fu, J., Zeng, Y.X., Cai, M.Y., and Xie, D. (2012). Increased intratumoral neutrophil in colorectal carcinomas correlates closely with malignant phenotype and predicts patients\u2019 adverse prognosis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030806"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jhep.2010.07.044","article-title":"Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection","volume":"54","author":"Li","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1002\/ijc.25892","article-title":"Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease","volume":"129","author":"Trellakis","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00262-018-2196-y","article-title":"Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer","volume":"67","author":"Barrera","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3324\/haematol.2015.141283","article-title":"Bone marrow fibrosis in myelofibrosis: Pathogenesis, prognosis and targeted strategies","volume":"101","author":"Zahr","year":"2016","journal-title":"Haematologica"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1158\/0008-5472.CAN-11-2449","article-title":"PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment","volume":"71","author":"Obermajer","year":"2011","journal-title":"Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.4049\/jimmunol.1103505","article-title":"MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN","volume":"188","author":"Liu","year":"2012","journal-title":"J. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"105818","DOI":"10.1016\/j.intimp.2019.105818","article-title":"SDF-1\/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy","volume":"75","author":"Jiang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e126853","DOI":"10.1172\/jci.insight.126853","article-title":"Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy","volume":"4","author":"Sun","year":"2019","journal-title":"JCI Insight"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/onc.2016.273","article-title":"Hepatic carcinoma-associated fibroblasts enhance immune suppression by facilitating the generation of myeloid-derived suppressor cells","volume":"36","author":"Deng","year":"2017","journal-title":"Oncogene"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e1062208","DOI":"10.1080\/2162402X.2015.1062208","article-title":"Expansion of myeloid derived suppressor cells correlates with number of T regulatory cells and disease progression in myelodysplastic syndrome","volume":"5","author":"Kittang","year":"2016","journal-title":"Oncoimmunology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/bs.mie.2019.07.022","article-title":"Detection and functional evaluation of arginase-1 isolated from human PMNs and murine MDSC","volume":"632","author":"Bronte","year":"2020","journal-title":"Methods Enzymol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1600-065X.2008.00608.x","article-title":"Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: Mechanisms and therapeutic perspectives","volume":"222","author":"Ochoa","year":"2008","journal-title":"Immunol. Rev."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2556\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:17:58Z","timestamp":1760109478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/14\/2556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,16]]},"references-count":43,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["cancers16142556"],"URL":"https:\/\/doi.org\/10.3390\/cancers16142556","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,16]]}}}